Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Cdc6 CRISPR/Cas9 KO Plasmid (h): sc-400796
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cdc6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Cdc6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cdc6 Antibody (180.2): sc-9964
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdc6 CRISPR/Cas9 KO Plasmid (h) | sc-400796 | 20 µg | $397.00 |
Overview
CDC6 encodes Cdc6, an essential ATPase that licenses DNA replication origins by assembling the pre-replication complex with ORC, CDT1, and MCM2–7 during G1 phase. Tight regulation of CDC6 through CDK activity and ubiquitin-mediated turnover coordinates the G1/S transition and helps enforce replication timing and genome stability checkpoints. Dysregulated CDC6 expression or control can promote rereplication stress, DNA damage signaling, and chromosomal instability, features frequently associated with oncogenic transformation. CDC6 is therefore widely studied in cell-cycle control, replication stress responses, and mechanisms linking altered origin licensing to genome instability.
Cdc6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CDC6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CDC6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CDC6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Cdc6 protein expression.
This CRISPR knockout system enables efficient generation of CDC6-deficient cell models for investigation of Cdc6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CDC6 exon(s) critical for Cdc6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CDC6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Cdc6 CRISPR/Cas9 KO Plasmid (h) and Cdc6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CDC6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Cdc6 HDR Plasmid (h) and Cdc6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CDC6 homology arms to support homology-directed repair at defined CDC6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.